Dergiler / Turkish Journal of Surgery / 2017 / Cilt: 33 - Sayı: 2

Lymphedema: From diagnosis to treatment

Sayfa
51–57
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

More studies are needed to reveal the exact biology of lymphedema to ensurecomplete understanding of the disease and improve outcomes.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Lymphedema is a chronic and progressive disorder resulting from impaired lymphatic system function.
📊
Temel Bulgular & Veri:In developedcountries, upper extremity lymphedema is mainly the consequence of breast cancer surgery in which axillary lymphnode dissection and radiation alter upper extremity lymphatic flow.Diagnosis of lymphedema is made clinically.
💡
Sonuç & Katkı:More studies are needed to reveal the exact biology of lymphedema to ensurecomplete understanding of the disease and improve outcomes.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Lymphedema is a chronic and progressive disorder resulting from impaired lymphatic system function. In developedcountries, upper extremity lymphedema is mainly the consequence of breast cancer surgery in which axillary lymphnode dissection and radiation alter upper extremity lymphatic flow.Diagnosis of lymphedema is made clinically. Nevertheless, there are numerous diagnostic tools available for diseasestaging. Recently, a new technology namely magnetic resonance lymphangiography has emerged in the medicalfield to assist in both diagnosis and management.There are non-surgical and surgical treatment options available. Non-surgical methods are always the first-linetreatment; however, surgical options can be explored in appropriate patients. Recent studies focus on the prevention of lymphedema using surgical techniques utilizing axillary reverse mapping to delineate arm lymphatics fromaxillary lymphatics.Finding the most suitable technique for each type of lymphedema with variable stages is one of the most complicated decisions for practitioners. More studies are needed to reveal the exact biology of lymphedema to ensurecomplete understanding of the disease and improve outcomes.

🔖

Bu Makaleye Atıf Yap

KAYIRAN, O., CRUZ, C. D. L., TANE, K., SORAN, A. (2017). Lymphedema: From diagnosis to treatment. Turkish Journal of Surgery, Cilt: 33 - Sayı: 2, 51–57. https://ajindex.com/articles/390541

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Basta MN, Gao LL, Wu LC. Operative treatment of peripheral lymphedema: a systematic meta-analysis of the efficacy and safety of lymphovenous microsurgery and tissue transplantation. Plast Reconstr Surg 2014; 133: 905-913. [CrossRef] Grabb and Smith's Plastic Surgery, 7th edition. In: Thorne CH, edi- tor, Wolters Kluwer Health, 2013. Lymphedema: Diagnosis and treatment, Chapter 97 p. 980-988.
  2. Tahan G, Johnson R, Mager L, Soran A. The role of occupational upper extremity use in breast cancer related upper extremity lymphedema. J Cancer Surviv 2010; 4: 15-19. [CrossRef] Noguchi M. Axillary reverse mapping for breast cancer. Breast Cancer Res Treat 2010; 119: 529-535. [CrossRef] Francis WP, Abghari P, Du W, Rymal C, Suna M, Kosir MA. Improv- ing surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node bi- opsy and axillary lymph node dissection. Am J Surg 2006; 192: 636-639. [CrossRef] DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta- analysis. Lancet Oncol 2013; 14: 500-515. [CrossRef] Armer JM, Stewart BR. Post-breast cancer lymphedema: inci- dence increases from 12 to 30 to 60 months. Lymphology 2010; 43: 118-127.
  3. Gur AS, Unal B, Ahrendt G, Gimbel ML, Kayiran O, Johnson R, et al. Risk Factors for Breast Cancer-Related Upper Extremity Lymph- edema: Is Immediate Autologous Breast Reconstruction one of them? Cent Eur J Med 2009; 4: 65-70. [CrossRef] Basta MN, Wu LC, Kanchwala SK, Serletti JM, Tchou JC, Kovach SJ, et al. Reliable prediction of postmastectomy lymphedema: the risk as- sessment tool evaluating lymphedema. Am J Surg 2016 Sep 7. doi: 10.1016/j.amjsurg.2016.08.016. [Epub ahead of print] [CrossRef] Kim M, Shin KH, Jung SY, Lee S, Kang HS, Lee ES, et al. Identifi- cation of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer. Can- cer Res Treat 2016; 48: 1330-1337. [CrossRef] Bernas M, Askew RL, Armer JM, Cormier JN. Lymphedema: How do we diagnose and reduce the risk of this dreaded complication of breast cancer treatment? Curr Breast Cancer Rep 2010; 2: 53-58. [CrossRef] NLN Medical Advisory Committee. The diagnosis and the treat- ment of lymphedema. In: Position statement of the national lymphedema network. Feb 2011. Available from: http://www. lymphnet.org/pdfDocs/nlntreatment.pdf. Mayrovitz, H. Assessing lymphedema by tissue indentation force and local ti